Demant (WILYY)
(Delayed Data from OTC)
$20.80 USD
0.00 (0.00%)
Updated Sep 5, 2024 09:57 AM ET
5-Strong Sell of 5 5
D Value A Growth D Momentum B VGM
Demant A/S Unsponsored ADR (WILYY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$N/A | $N/A | $N/A | N/A% |
Price Target
Demant A/S Unsponsored ADR does not have any price target set by analysts.
Analyst Price Targets ()
Broker Rating
Demant A/S Unsponsored ADR currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 3.33 a month ago based on three recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.50 | 2.50 | 3.33 | 3.33 | 3.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/28/2024 | UBS | Graham Doyle | Not Available | Strong Buy |
8/23/2024 | Not Identified | Not Identified | Moderate Sell | Hold |
3/15/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.50 |
# of Recs in ABR | 4 |
Average Target Price | NA |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 86 of 253 |
Current Quarter EPS Est: | NA |